Analysts predict that Menlo Therapeutics Inc (NASDAQ:MNLO) will announce earnings of ($0.84) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Menlo Therapeutics’ earnings, with estimates ranging from ($0.87) to ($0.81). Menlo Therapeutics reported earnings of ($0.36) per share during the same quarter last year, which would indicate a negative year over year growth rate of 133.3%. The business is scheduled to report its next earnings results on Wednesday, August 7th.
On average, analysts expect that Menlo Therapeutics will report full-year earnings of ($3.37) per share for the current fiscal year, with EPS estimates ranging from ($3.52) to ($3.19). For the next financial year, analysts expect that the business will post earnings of ($2.46) per share, with EPS estimates ranging from ($2.87) to ($1.94). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Menlo Therapeutics.
Menlo Therapeutics (NASDAQ:MNLO) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.81).
Shares of MNLO traded down $0.10 during trading on Friday, reaching $6.02. 415 shares of the company traded hands, compared to its average volume of 76,280. Menlo Therapeutics has a twelve month low of $3.74 and a twelve month high of $12.00. The stock has a market cap of $148.16 million, a PE ratio of -2.55 and a beta of 2.95.
Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. increased its stake in Menlo Therapeutics by 16.5% in the third quarter. BlackRock Inc. now owns 528,035 shares of the company’s stock valued at $5,201,000 after acquiring an additional 74,683 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Menlo Therapeutics by 365.6% in the third quarter. JPMorgan Chase & Co. now owns 596,959 shares of the company’s stock valued at $5,879,000 after acquiring an additional 468,759 shares during the last quarter. Renaissance Technologies LLC bought a new position in Menlo Therapeutics in the third quarter valued at $308,000. TIAA CREF Investment Management LLC bought a new position in Menlo Therapeutics in the third quarter valued at $184,000. Finally, Vanguard Group Inc. increased its stake in Menlo Therapeutics by 75.3% in the third quarter. Vanguard Group Inc. now owns 458,931 shares of the company’s stock valued at $4,521,000 after acquiring an additional 197,188 shares during the last quarter. Institutional investors and hedge funds own 80.05% of the company’s stock.
About Menlo Therapeutics
Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.